New drug indication approval - November 2022

Product Name

ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL

Active Ingredient

Trastuzumab deruxtecan

Product Registrant

ASTRAZENECA SINGAPORE PTE LTD

Date of Approval

30/11/2022

Indications:

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

*Evaluated as part of Project Orbis